23 May 2013
Keywords: sosei/vectura, drug, may, act, faster, spiriva, japanese
Article | 13 October 2008
Japanese biopharmaceutical company Sosei and its UK-based partner Vectura presented data from two Phase II studies evaluating the chronic
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 October 2008
22 May 2013
© 2013 thepharmaletter.com